





Placental hormones like progesterone, growth hormone, corticotropin-releasing hormone and placental lactogen lower insulin sensitivity of target tissues, increase insulin resistance hence the induction of diabetes during pregnancy [15]. Hence, a sound and healthy pregnancy requires a normal interplay between the pituitary, thyroid, adrenal and parathyroid glands to meet the metabolic activities during pregnancy [16]. Although GDM often resolves after child delivery, there is an over sevenfold risk of developing type 2 diabetes mellitus later in life compared with those with normal glycemic levels [17]. Hypoglycemic agents (metformin, sulfonylureas, glyburide) and insulin are used to improve the conditions of GDM mothers when exercise and diet fail to reduce blood glucose [18]. There have been concerns about the safety and efficiency of hypoglycemic drugs in pregnant women. The oral hypoglycemic agents have been reported to have gastrointestinal (nausea, flatulence,

diarrhea, vomiting) side effects. Medicinal plants are safe therapeutic agents that have been successfully utilized in managing and treating different diseases. This review elucidates some of the alternative ways of managing gestational diabetes mellitus.

#### METHODOLOGY

Different databases such as PubMed, Scopus, Web of Science, ScienceDirect, ResearchGate, Google Scholar were used in this review article with the following keywords: “alternative treatment”, “gestational diabetes”, “bioactive compounds”, “medicinal plants”, “herbal treatment” and “functional foods”. The references for this review were selected based on these criteria: articles published between 2010-2023, full-text original articles, animal and human studies and relevance to the review topic.

**Table 1:** Summary of studies on the various alternative treatments of gestational diabetes mellitus

S/N	Medicinal Plant/Bioactive compounds	Research Sample	Description	Outcome	References
1.	<i>Abelmoschus esculentus</i> (L.) Moench.	Pregnant rats	27 pregnant female rats were induced with GDM using streptozotocin (STZ). 200 mg/kg okra extract was administered orally for 19 days	Okra extract significantly reduced triglycerides, fasting blood glucose and insulin, total cholesterol, low-density lipoprotein; increased high-density lipoproteins; pancreatic and hepatic glutathione peroxidase, superoxide dismutase and catalase	[12]
2.	<i>Lotus leaf selenium (Se)-polysaccharide (LLP)</i>	Pregnant wistar rats	Pregnant wistar rats were induced with GDM using 2% streptozotocin at 40 mg/kg. The GDM groups were treated with 50 mg/kg and 100 g/kg of LLP for 14 days	Hepatic SOD, CAT, glutathione, glutathione peroxidase, HDL and glycogen were significantly increased.  FBG, FINS, total cholesterol, LDL and triglycerides were reduced	[76]
3	Soybean oligosaccharides (SBOS)	Pregnant women	46 pregnant women with GDM were treated with 10 g SBOS orally	SBOS significantly increased SOD, GPx, CAT and adiponectin while TBARS, insulin, HOMA-IR and fasting insulin were decreased	[79]





after 4 weeks of intervention [28]. Nine weeks of administration with garlic reduced serum C-reactive protein high-sensitivity (hs-CRP) and increased plasma GSH with no significant difference in plasma total antioxidant capacity (TAC), serum lipid profiles, HOMA-IR levels and homeostatic model assessment of  $\beta$ -cell function (HOMA- $\beta$ ) index in the pregnant women. Insulin and FBG levels were significantly decreased ( $P>0.05$ ) [26].

**Hibiscus rosa sinensis L.:** *H.rosa sinensis* is an ornamental plant and the flower has been discovered to have wound healing, antidepressant [29], antioxidant and antibacterial [30] effects. Afiune *et al.* [31] administered aqueous extract of *H.rosa sinensis* at doses of 100, 200 and 400 mg/kg to diabetic pregnant rats, a significant increase in body weight was observed but with no change in the blood glucose level compared to the untreated group ( $P<0.05$ ). A significant reduction in very low-density lipoproteins (VLDL-c) and triglycerides levels and a significant increase in HDL-c level were reported. The SOD activity was significantly increased with no change in MDA, CAT and GSH levels after treatment with the extract ( $P<0.05$ ). Administration with the extract however increased embryo loss and maternal diabetes-induced fetal abnormalities. Doses of *H.rosa sinensis* up to 2000 mg/kg have no toxic effects [32].

**Ginger (*Zingiber officinale Roscoe*):** Ginger, a plant used as spice or seasoning while cooking has been discovered to have antioxidant, anti-inflammatory, hypolipidemic, insulinotropic and hypoglycemic effects [33]. Animals administered up to the dose of 3000 mg/kg showed no sign of toxicity [34]. Raouia *et al.* [35] conducted a study whereby pregnant diabetic rats were orally treated with ginger extract (80 mg/kg) for 6 days. Ginger was discovered to significantly reduce maternal elevated blood glucose, increase body weight ( $P<0.001$ ), recognition and memory in offspring.

**Olive leaf extract:** Olive leaves (*olea europaea L. folium*) are considered to possess antioxidant, anti-hypertensive, hypoglycemic, antimicrobial, and anti-atherosclerotic

properties [36]. The role of olive extract in the renal tissues of diabetes-induced pregnant mice and their offspring was investigated by Mohammed *et al.* [37]. It was discovered that 100 mg/kg olive leaf extract (OLE) inhibited maternal body weight loss, increased placental weight leading to an elevated placenta/fetal ratio, reduced serum creatinine and urea levels ( $P< 0.05$ ), ameliorated histopathological changes in the renal tissues of both mother and fetus and reduced Angiotensin II content in the renal tissue. Doses around 100, 200, 400 and 1000 mg/kg are considered safe [38].

### BIOACTIVE COMPOUNDS

**Cinnamaldehyde:** Cinnamaldehyde is derived from cinnamon bark that possesses antihyperglycemic, anti-inflammatory and antioxidant potentials [39]. According to Hosni *et al.* [8], treatment of GDM rats with cinnamaldehyde (20mg/kg) for a duration of 4 weeks resulted in a significant increase in the weight of the pregnant diabetic rats after the reduced body weight observed due to feeding with fatty-sucrose diet. Cinnamaldehyde lowered the FINS and FBG levels compared with the untreated group. In the gestational diabetic rats administered cinnamaldehyde, liver glycogen and HDL-cholesterol significantly increased while fructosamine, triglycerides and total cholesterol levels were significantly lowered compared to the untreated gestational diabetic rats ( $P<0.05$ ). Adiponectin levels significantly increased while leptin and TNF- $\alpha$  significantly reduced post-cinnamaldehyde administration ( $P<0.05$ ). Furthermore, MDA and nitrite levels were significantly decreased while GSH and CAT levels were significantly elevated after cinnamaldehyde treatment. Expression of peroxisome proliferator-activated receptor gamma (PPAR $\gamma$ ) mRNA was significantly increased in the treated group. Finally, the number of live fetuses significantly increased in the treated group with a significant decrease in implantation loss, fetal insulin, and fetal glucose ( $P<0.05$ ) [8]. The lethal dose of cinnamaldehyde is 0.6-3.4 g/kg.bw [40].

**Naringenin:** Naringenin, a polyphenol abundant in grapes and citrus fruits, was discovered to possess antidiabetic [41-42], anti-inflammatory [43] and antioxidant activities [44]. Administration of naringenin up to 1250 mg/kg for 6 months had no observed adverse effects [45]. In in vitro human model, Nguyen-Ngo *et al.* [46] investigated the effect of naringenin (400  $\mu$ m) on insulin resistance, antioxidant and inflammation expression in placenta, skeletal muscle and adipose tissue obtained from normal glucose-tolerant women at elective caesarean section. These tissues were stimulated with tumor necrosis factor to simulate a GDM-like environment. Pregnant heterozygous leptin receptor-deficient *db/+* mice were used for the in vivo GDM model. The mice were administered 50 mg/kg naringenin from gestation day 10-18. The administration of naringenin significantly enhanced insulin-stimulated glucose uptake in the skeletal muscle, decreased TNF- $\alpha$  expression and increased antioxidant mRNA expression with no effect on the chemokines and pro-inflammatory cytokines but reduced interleukin-1A mRNA expression. Treatment with naringenin enhanced glucose tolerance and fasting glucose level in the GDM mice. Activation of NF- $\kappa$ B was inhibited while catalase and SOD mRNA expressions were upregulated ( $P < 0.05$ ).

**Resveratrol:** Resveratrol (RESV), a natural polyphenol present in vegetables and fruits like berries, grapes [47] has been discovered to possess anti-hyperglycemic, anti-inflammatory and antioxidant potentials in diabetes-induced rats [48-50]. Resveratrol supplements when consumed throughout the gestation period decreased obesity, liver triglycerides and enhanced insulin sensitivity in the mature offspring [51]. Brawerman *et al.* [52] discovered that RESV supplementation in the mother reduced blood glucose, improved glucose tolerance, insulin sensitivity and inhibited glucose-stimulated insulin production during gestation with no effect on body weight. RESV can cross the placenta, therefore this same study investigated the effect on fetal

development and normal litter sizes and sex distributions were reported. In newborn males treated with RESV, macrosomia and obesity were prevented but not in female newborns compared with the untreated group. Although a study by Ros *et al.* [53] reported otherwise whereby RESV prevented obesity in the female newborns but not the males of mothers fed high-fat diet. During GDM, prenatal administration of RESV inhibited the development of liver steatosis in the dams by improving PPAR- $\alpha$  expression in the hepatic tissues. GDM has adverse effects on the pancreatic islet thereby impairing insulin and glucagon production. However, RESV supplementation in pregnant diabetic mice resulted in offspring with similar islet size and structure as the lean offspring [52]. Pregnant diabetic mice administered with 10 mg/kg/day resveratrol had improved glycemic index and were responsive to insulin. Increased survival rates and reduced body weight were observed in their offspring. There was also reduced hepatic glucose production as a result of an upregulation in hepatic AMPK which led to reduced expression of glucose-6-phosphatase [54]. In pregnant mice that consumed 0.2% RESV supplement mixed with high-fat diet (HFD), their male offspring exhibited enhanced insulin sensitivity and decreased body weight compared with those who consumed HFD without RESV supplementation [55].

**Berberine:** Berberine, an isoquinoline protoalkaloid derived from rhizome coptidis, turmeric, Oregon grape, barberry is discovered to have antidiabetic and anticancer potentials [56]. According to Li *et al.* [57], berberine (100 mg/kg/day) administered to GDM rats from 7<sup>th</sup> to 20<sup>th</sup> gestation day reduced insulin resistance, fetal loss, maternal body weight, placental and fetal weight in comparison to the untreated group. It also reduced CRP and TNF- $\alpha$  levels, expression of IKK $\beta$ , nuclear translocation of NF- $\kappa$ B /P65 and modified the phosphorylation of AKT, JNK and IRS-1 in the hepatic tissues of the pregnant diabetic rats.

**Curcumin:** Curcumin, a polyphenol derived from the rhizomes of *curcuma longa L.* has been reported to possess anti-diabetic, antioxidant, neuroprotective, antimicrobial, antidepressant, and anti-inflammatory properties [58-61]. In human clinical trials, up to 2 g/day curcumin was considered safe with no toxicity [62]. Low dose (50 mg/kg) and high dose (100 mg/kg) of curcumin were orally administered to gestational diabetic mice. The high dose significantly reduced fasting blood glucose and insulin levels ( $P < 0.05$ ). The levels of hepatic TBARS were reduced while GSH, SOD and CAT and glycogen were significantly increased following curcumin (100 mg/kg) administration ( $P < 0.05$ ). The same study also reported that a high dose of curcumin could improve litter size and offspring body weight. Curcumin also enhanced the activation of AMPK-related proteins and reduced G6Pase activity in the offspring [63].

**Specnuezhenide (SPZ):** Specnuezhenide (SPZ), a bioactive compound isolated from the *Ligustrum lucidum* fruit has been reported to have anti-inflammatory, antioxidant, neuroprotective and immune-regulatory properties [64-65]. SPZ significantly reduced blood glucose, insulin, and resistin in GDM rats. Also, treatment with STZ significantly reduced the expression of NF- $\kappa$ B mRNA and increased I $\kappa$ B expression in pancreatic  $\beta$ -cells. Expression of Caspase-3 and Bax were significantly reduced while Bcl-2 expression was significantly elevated in the  $\beta$ -cells of the pancreas [66].

**Ganoderma lucidum Karst:** *Ganoderma lucidum* (GL) which is comprised of different bioactive compounds (polysaccharides, polyphenols, sterols and terpenoids) is a medicinal mushroom and has been discovered to be effective in regulating blood glucose [67-69]. Viroel *et al.* [70], reported that GL (100 mg/kg) administered for 19 days had no effect on insulin and total cholesterol levels in streptozotocin-induced diabetic pregnant rats but significantly reduced ALT, AST and triglycerides levels ( $P < 0.05$ ). The levels of CAT was significantly increased while

TBARS level was significantly reduced following GL administration ( $P < 0.05$ ). GL shows no signs of toxicity at doses up to 5000mg/kg [71].

**Puerarin:** Puerarin, an isoflavonoid isolated from the root of *Puerarin lobata* has been discovered to possess hypoglycemic and anti-inflammatory potentials. It is also suggested to be effective in treating myocardial infarction, arteriosclerosis, and diabetes mellitus [72-73]. Puerarin (0.25 g/kg) was administered to high-fat diet fed rats with STZ-induced GDM for 2 weeks, it was discovered that insulin receptor substrate 1 (IRS-1) expression was significantly upregulated ( $P < 0.01$ ) while the expression levels of TLR4 and MyD88 were downregulated. The levels of TNF- $\alpha$  and phosphorylated NF- $\kappa$ B were also reduced ( $P < 0.05$ ) [74].

## FUNCTIONAL FOODS

**Lotus leaf selenium (Se)-polysaccharide:** Lotus leaf selenium (Se)-polysaccharide (LLP) has been discovered to have hypolipidemic, antidiabetic, ant obesity and anti-inflammatory potentials [75]. Pregnant diabetic rats administered 50 and 100 mg/kg of LLP for 14 days had higher levels of HDL ( $P < 0.05$ ) and liver glycogen and lower FBG and FINS, total cholesterol (TC), LDL and triglycerides levels ( $P < 0.05$ ). This suggested that LLP improves insulin sensitivity [76].

The administration of LLP significantly increased SOD, catalase, GSH and GPx ( $P < 0.05$ ) in the hepatic tissues. The result was almost the same as those of the normal-pregnancy control [76]. No toxic effects or death were observed during this study.

**Soybean oligosaccharides:** Soybean oligosaccharides (SBOS) are potential prebiotics isolated in soybean seeds composed of sucrose, raffinose and stachyose [77]. The SBOS reduced oxidative stress and aberrant lipid profile stimulated by high-fat diet [78]. Fei *et al.* [79], investigated the effects of 10 g SBOS in 200-300 mL of warm water on insulin resistance and antioxidant



enzymes in pregnant women with GDM and it was reported that SBOS significantly ( $P < 0.01$ ) increased SOD, CAT, GPx levels while the thiobarbituric acid reactive substances (TBARS) level was significantly ( $P < 0.01$ ) reduced. There was a significant reduction in the insulin levels of SBOS-treated group in comparison with the GDM group. Homeostatic model assessment for insulin resistance (HOMA-IR) and FINS were significantly lower, adiponectin level was significantly higher ( $P < 0.01$ ) while fasting plasma glucose (FPG) and islet  $\beta$ -cells function index (HBCI) were reduced although with no significant difference [79].

**Soy protein:** Consumption of soy diet containing 0.8-g/kg protein (35% animal protein, 35% soy protein, 30% other plant proteins) in pregnant diabetic women for 6 weeks resulted in a significantly reduced level of serum insulin, HOMA-IR, fasting plasma glucose, VLDL-C and triglycerides ( $P < 0.001$ ) with a significant increase in plasma GSH and total antioxidant capacity ( $P > 0.05$ ) with no significant difference in hs-CRP, LDL-C, HDL-C, nitric oxide (NO) and MDA levels compared with the pregnant diabetic group that did not consume soy protein [80].

**Vitamin D and Evening primrose oil (EPO):** Vitamin D is vital in the regulation of calcium, and it plays a significant role in GDM because calcium signaling is essential in insulin production from the  $\beta$ -cell. It improves immune functions and possesses anti-inflammatory activity [81]. Omega-6 essential fatty acids like linoleic acid and gamma-linolenic acid are abundant in EPO which has been reported to reduce labor, increase HDL, total cholesterol levels. Individually, vitamin D supplements reduced insulin resistance while EPO improved lipid profile, hence Jamilian *et al.* [82] co-administered EPO (1000 mg) and vitamin D3 (1000 IU) in gestational diabetic women for 6 weeks. This resulted in HOMA-IR, serum insulin levels, HOMA and fasting plasma glucose being significantly reduced in comparison to the placebo ( $P < 0.05$ ). Serum triacylglycerol (TAG), VLDL, total cholesterol, LDL levels were significantly reduced

( $P < 0.001$ ) with no significant difference in HDL were observed after joint administration with EPO and vitamin D.

**N-3 fatty acids from flaxseed oil:**  $\alpha$ -linolenic acid (ALA), the precursor of polyunsaturated fatty acids (PUFAs), eicosatetraenoic acid (EPA) and docosahexaenoic acid (DHA) is abundant in flaxseed oil. Flaxseed oil has been suggested to improve immunity, reduce lipogenesis, and possess antioxidant potential [83]. Jamilian *et al.* [84] investigated the effect of n-3 fatty acids from flaxseed oil in gestational diabetic women. The gestational diabetic women received 2 capsules with 1000 mg/d n-3 fatty acid from flaxseed oil containing 400 mg  $\alpha$ -linolenic acid in each capsule and it was discovered to significantly reduce fasting plasma glucose, HOMA-IR, TAG, VLDL-C, total cholesterol levels, hs-CRP, malondialdehyde (MDA) and increase GSH and total NO levels ( $P < 0.001$ ). Expression of tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) and interleukin-1 (IL-1) were down-regulated after administration with flaxseed oil. It had no effect on TAC and gene expression of transforming growth factor  $\beta$  (TGF- $\beta$ ) and vascular endothelial growth factor (VEGF).

## CONCLUSION

Gestational diabetes mellitus is a common metabolic disease that can affect the mother and child. This review, therefore, highlights some alternative treatments reported to be effective in the management of gestational diabetes mellitus. Some of the modes of action include the reduction of fasting blood glucose and insulin, improving lipid and pro-inflammatory cytokine profiles, increasing placenta/fetal ratio. However, more basic, and clinical studies should be done to further validate the safety, efficacy and discover more mechanisms of action of these medicinal plants and compounds.

**Abbreviations:** GDM: Gestational Diabetes Mellitus, TNF- $\alpha$ : Tumor necrosis factor- $\alpha$ , IL-6: Interleukin-6, LDL: Low-

density lipoprotein, FINS: Fasting insulin, FBG: Fasting blood glucose, HDL: High-density lipoprotein, GPx: Glutathione peroxidase, SOD: Superoxide dismutase, CAT: Catalase, TC- Total cholesterol, TBARS: thiobarbituric acid reactive substances, FPG:Fasting plasma glucose, TAC: total antioxidant capacity, MDA: malondialdehyde, NO: Nitric oxide, TAG:triacylglycerol.

**Competing interests:** The authors have no financial interests or conflicts of interest.

**Authors' contribution:** All authors contributed to this study.

**Acknowledgement and Funding:** No funding was received for this review.

## REFERENCES

- Lappas M. GSK3 $\beta$  is increased in adipose tissue and skeletal muscle from women with gestational diabetes where it regulates the inflammatory response. *PLoS One* 2014, 9(12): e115854. DOI: <https://doi.org/10.1371/journal.pone.0115854>.
- Johns EC, Denison FC, Norman JE, Reynolds RM. Gestational diabetes mellitus: mechanisms, treatment, and complications. *Trends in Endocrinology & Metabolism* 2018, 29(11): 743-754. DOI: <https://doi.org/10.1016/j.tem.2018.09.004>.
- Suntorn R, Panichkul P. Prevalence of gestational diabetes mellitus detected by International Association of the Diabetes and Pregnancy Study Groups (IADPSG) criteria in Phramongkutkiao hospital. *Thai Journal of Obstetrics and Gynaecology* 2015, 23(3): 144-150. DOI: <https://doi.org/10.14456/tjog.2015.24>.
- Tsabang N., Djeufack L.W.T., Yedjou C.G., Tchounwou P.B. Importance of food plants in the prevention and treatment of diabetes in Cameroon. *Bioactive Compounds in Health and Disease* 2019, 2(2): 11-26. DOI: <https://doi.org/10.31989/bchd.v2i2.554>.
- Wani K, Sabico S, Alnaami AM, Al-Musharaf S, Fouda MA, Turkestani IZ, Al-Ajlan A, et al. Early-pregnancy metabolic syndrome and subsequent incidence in gestational diabetes mellitus in Arab women. *Frontiers in Endocrinology* 2020, 11: 98. DOI: <https://doi.org/10.3389/fendo.2020.00098>.

- Plows JF, Stanley JL, Baker PN, Reynolds CM, Vickers MH. The pathophysiology of gestational diabetes mellitus. *Int J Mol Sci.* 2018;19(11):1–21. DOI: <https://doi.org/10.3390/ijms19113342>.
- de Mendonça EL, Fragoso MB, de Oliveira JM, Xavier JA, Goulart MO, de Oliveira AC. Gestational diabetes mellitus: the crosslink among inflammation, nitroxidative stress, intestinal microbiota and alternative therapies. *Antioxidants.* 2022 Jan 7;11(1):129. DOI: <https://doi.org/10.3390/antiox11010129>.
- Hosni AA, Abdel-Moneim AA, Abdel-Reheim ES, Mohamed SM, Helmy H. Cinnamaldehyde potentially attenuates gestational hyperglycemia in rats through modulation of PPAR $\gamma$ , proinflammatory cytokines and oxidative stress. *Biomedicine & Pharmacotherapy* 2017, 88: 52-60. DOI: <https://doi.org/10.1016/j.biopha.2017.01.054>.
- Baeyens L, Hindi S, Sorenson R. L, German MS.  $\beta$ -Cell adaptation in pregnancy. *Diabetes, Obesity and Metabolism* 2016, 18: 63-70. DOI: <https://doi.org/10.1111/dom.12716>.
- Abell SK, De Courten B, Boyle JA, Teede HJ. Inflammatory and other biomarkers: role in pathophysiology and prediction of gestational diabetes mellitus. *International journal of molecular sciences* 2015, 16(6): 13442-13473. DOI: <https://doi.org/10.3390/ijms160613442>.
- McIntyre HD, Catalano P, Zhang C, Desoye G, Mathiesen ER, Damm P. Gestational diabetes mellitus. *Nature reviews Disease primers* 2019, 5(1): 1-19.
- Tian ZH, Miao FT, Zhang X, Wang QH, Lei N, Guo LC. Therapeutic effect of okra extract on gestational diabetes mellitus rats induced by streptozotocin. *Asian Pacific journal of tropical medicine* 2015, 8(12): 1038-1042. DOI: <https://doi.org/10.1016/j.apitm.2015.11.002>.
- Matuszek B, Lenart-Lipińska M, Burska A, Paszkowski T, Smoleń A, Nowakowski A. Increased serum insulin-like growth factor-1 levels in women with gestational diabetes. *Advances in medical sciences* 2011, 56(2): 200-206. DOI: <https://doi.org/10.2478/v10039-011-0046-7>.
- Agarwal P, Morriveau TS, Kereliuk SM, Doucette CA, Wicklow BA, Dolinsky VW. Maternal obesity, diabetes during pregnancy and epigenetic mechanisms that influence the developmental origins of cardiometabolic disease in the offspring. *Critical reviews in clinical laboratory sciences* 2018, 55(2): 71-101. DOI: <https://doi.org/10.1080/10408363.2017.1422109>.
- Law KP, Zhang H. The pathogenesis and pathophysiology of gestational diabetes mellitus: Deductions from a three-part

- longitudinal metabolomics study in China. *Clinica Chimica Acta* 2017, 468: 60-70. DOI: <https://doi.org/10.1016/j.cca.2017.02.008>.
16. Daflapurkar SB. High risk cases in obstetrics. *JP Medical Ltd*, 2014: 61-75.
  17. Guo J, Chen JL, Whittemore R, Whitaker E. Postpartum lifestyle interventions to prevent type 2 diabetes among women with history of gestational diabetes: a systematic review of randomized clinical trials. *Journal of women's health*. 2016, 25(1):38-49. DOI: <https://doi.org/10.1089/jwh.2015.5262>.
  18. Brawerman GM, Dolinsky VW. Therapies for gestational diabetes and their implications for maternal and offspring health: evidence from human and animal studies. *Pharmacological Research* 2018, 130: 52-73. DOI: <https://doi.org/10.1016/j.phrs.2018.02.002>.
  19. Dubey P, Mishra S. A review on: Diabetes and okra (*Abelmoschus esculentus*). *J. Med. Plants Stud*. 2017;5(3):23-6.
  20. Yang LW, Fattepur S, Nilugal KC, Asmani F, Yusuf E, Ghani MNA, Abdullah I. Neuroprotection of *abelmoschus esculentus* l. against diabetic neuropathy. *Asian journal of pharmaceutical and clinical research* 2018:28-31. DOI: <http://dx.doi.org/10.22159/ajpcr.2018.v11s3.30023>.
  21. Kuruwita Arachchige SV, Uluwaduge DI, Premakumara S, Wijayabandara J. Cardio protective activity of *Abelmoschus esculentus* (Okra). *Int. J. Food Sci. Nutr* 2018, 3(5): 39-43.
  22. Sereno AB, Pinto CD, Andrade FA, da Silva MAB, Garcia AC, Krüger CCH, de Messias Reason IJ. Effects of okra (*Abelmoschus esculentus* (L.) Moench) on glycemic markers in animal models of diabetes: A systematic review. *Journal of Ethnopharmacology* 2022, 298: 115544. DOI: <https://doi.org/10.1016/j.jep.2022.115544>.
  23. Fan S, Zhang Y, Sun Q, Yu L, Li M, Zheng B, Wu X, et al. Extract of okra lowers blood glucose and serum lipids in high-fat diet-induced obese C57BL/6 mice. *The Journal of nutritional biochemistry* 2014, 25(7): 702-709. DOI: <https://doi.org/10.1016/j.jnutbio.2014.02.010>.
  24. Sabitha V, Ramachandran S, Naveen KR, Panneerselvam K. Antidiabetic and antihyperlipidemic potential of *Abelmoschus esculentus* (L.) Moench. in streptozotocin-induced diabetic rats. *Journal of pharmacy and bioallied sciences*. 2011, 3(3):397. DOI: <https://doi.org/10.4103%2F0975-7406.84447>.
  25. Kumar R, Chhatwal S, Arora S, Sharma S, Singh J, Singh N, Bhandari V, et al. Antihyperglycemic, antihyperlipidemic, anti-inflammatory and adenosine deaminase-lowering effects of garlic in patients with type 2 diabetes mellitus with obesity. *Diabetes, metabolic syndrome and obesity: targets and therapy* 2013, 6:49-56. DOI: <https://doi.org/10.2147/DMSO.S38888>.
  26. Aalami-Harandi R, Karamali M, Asemi, Z. The favorable effects of garlic intake on metabolic profiles, hs-CRP, biomarkers of oxidative stress and pregnancy outcomes in pregnant women at risk for pre-eclampsia: randomized, double-blind, placebo-controlled trial. *The Journal of Maternal-Fetal & Neonatal Medicine* 2015, 28(17): 2020-2027. DOI: <https://doi.org/10.3109/14767058.2014.977248>.
  27. Lawal B, Shittu OK, Oibiokpa FI, Mohammed H, Umar SI, Haruna GM. Antimicrobial evaluation, acute and sub-acute toxicity studies of *Allium sativum*. *Journal of Acute Disease*. 2016 Jul 1;5(4):296-301. DOI: <https://doi.org/10.1016/j.joad.2016.05.002>.
  28. Faroughi F, Charandabi SMA, Javadzadeh Y, Mirghafourvand M. Effects of Garlic Pill on Blood Glucose Level in Borderline Gestational Diabetes Mellitus: A Triple Blind, Randomized Clinical Trial. *Iranian Red Crescent Medical Journal* 2018, 20(7): e60675.
  29. Khalid L, Rizwani GH, Sultana V, Zahid H, Khursheed R, Shareef H. Antidepressant activity of ethanolic extract of *Hibiscus rosa sinensis* Linn. *Pakistan Journal of Pharmaceutical Sciences* 2014, 27(5): 1327-1331.
  30. Nayak D, Ashe S, Rauta PR, Nayak B. Biosynthesis, characterisation and antimicrobial activity of silver nanoparticles using *Hibiscus rosa-sinensis* petals extracts. *IET nanobiotechnology* 2015, 9(5): 288-293. DOI: <https://doi.org/10.1049/iet-nbt.2014.0047>.
  31. Afiune LAF, Leal-Silva T, Sinzato YK, Moraes-Souza RQ, Soares TS, Campos KE, Fujiwara RT, et al. Beneficial effects of *Hibiscus rosa-sinensis* L. flower aqueous extract in pregnant rats with diabetes. *PLoS One* 2017, 12(6): e0179785. DOI: <https://doi.org/10.1371/journal.pone.0179785>.
  32. Al-Snafi AE. Chemical constituents, pharmacological effects and therapeutic importance of *Hibiscus rosa-sinensis*-A review. *IOSR Journal of Pharmacy*. 2018;8(7):101-19.
  33. Balogun FO, AdeyeOluwa ET, Ashafa AOT. Pharmacological potentials of ginger. *Ginger Cultivation and Its Antimicrobial and Pharmacological Potentials*. IntechOpen 2019: 131-149
  34. Yamprasert R, Chanvimalueng W, Mukkasombut N, Itharat A. Ginger extract versus Loratadine in the treatment of allergic rhinitis: a randomized controlled trial. *BMC*

- complementary medicine and therapies. 2020, 20:1-1. DOI: <https://doi.org/10.1186/s12906-020-2875-z>.
35. Raouia M, Habiba F, Abdelkrim T. Effect of ginger on hyperglycemia induced by streptozotocin in pregnant rats and postnatal neurodevelopment of their offspring. *ACTA Pharmaceutica Scientia* 2020, 58(1): 101-111. DOI: <https://doi.org/10.23893/1307-2080.APS.05807>.
  36. Cavaca LA, López-Coca IM, Silvero G, & Afonso, CA. The olive-tree leaves as a source of high-added value molecules: Oleuropein. *Studies in natural products chemistry* 2020, 64: 131-180. DOI: <https://doi.org/10.1016/B978-0-12-817903-1.00005-X>.
  37. Mohammed HA., Okail HA., Ibrahim MA., Emam NM. Influences of olive leaf extract in the kidney of diabetic pregnant mice and their offspring. *The Journal of Basic and Applied Zoology* 2018, 79(1): 1-13. DOI: <https://doi.org/10.1186/s41936-018-0024-8>.
  38. Guex CG, Reginato FZ, Figueredo KC, da da Silva AR, Pires FB, da Silva Jesus R, Lhamas CL, Lopes GH, de Freitas Bauermann L. Safety assessment of ethanolic extract of *Olea europaea* L. leaves after acute and subacute administration to Wistar rats. *Regulatory Toxicology and Pharmacology*. 2018, 95:395-9. DOI: <https://doi.org/10.1016/j.yrtph.2018.04.013>.
  39. Subash-Babu P, Alshatwi AA, Ignacimuthu S. Beneficial antioxidative and antiperoxidative effect of cinnamaldehyde protect streptozotocin-induced pancreatic  $\beta$ -cells damage in wistar rats. *Biomolecules & therapeutics* 2014, 22(1): 47-54. DOI: <https://doi.org/10.4062%2Fbiomolther.2013.100>.
  40. Zhu R, Liu H, Liu C, Wang L, Ma R, Chen B, Li L, Niu J, Fu M, Zhang D, Gao S. Cinnamaldehyde in diabetes: A review of pharmacology, pharmacokinetics and safety. *Pharmacological research*. 2017, 122:78-89. DOI: <https://doi.org/10.1016/j.phrs.2017.05.019>.
  41. Ren B, Qin W, Wu F, Wang S, Pan C, Wang L, Zeng B, et al. Apigenin and naringenin regulate glucose and lipid metabolism, and ameliorate vascular dysfunction in type 2 diabetic rats. *European journal of pharmacology* 2016, 773: 13-23. DOI: <https://doi.org/10.1016/j.ejphar.2016.01.002>.
  42. Krishnamoorthy RM, Venkatraman AC. Polyphenols activate energy sensing network in insulin resistant models. *Chemico-biological interactions* 2017, 275: 95-107. DOI: <https://doi.org/10.1016/j.cbi.2017.07.016>.
  43. Pinho-Ribeiro FA, Zarpelon AC, Fattori V, Manchope MF, Mizokami SS, Casagrande R, Verri Jr WA. Naringenin reduces inflammatory pain in mice. *Neuropharmacology* 2016, 105: 508-519. DOI: <https://doi.org/10.1016/j.neuropharm.2016.02.019>.
  44. Roy S, Ahmed F, Banerjee S, Saha U. Naringenin ameliorates streptozotocin-induced diabetic rat renal impairment by downregulation of TGF- $\beta$ 1 and IL-1 via modulation of oxidative stress correlates with decreased apoptotic events. *Pharmaceutical biology* 2016, 54(9): 1616-1627. DOI: <https://doi.org/10.3109/13880209.2015.1110599>.
  45. Chen R, Qi QL, Wang MT, Li QY. Therapeutic potential of naringin: an overview. *Pharmaceutical biology*. 2016 Dec 1;54(12):3203-10. DOI: <https://doi.org/10.1080/13880209.2016.1216131>.
  46. Nguyen-Ngo C, Willcox JC, Lappas M. Anti-diabetic, anti-inflammatory, and antioxidant effects of naringenin in an in vitro human model and an in vivo murine model of gestational diabetes mellitus. *Molecular nutrition & food research* 2019, 63(19): 1900224. DOI: <https://doi.org/10.1002/mnfr.201900224>.
  47. Dolinsky VW, Dyck JR. Experimental studies of the molecular pathways regulated by exercise and resveratrol in heart, skeletal muscle and the vasculature. *Molecules* 2014, 19(9): 14919-14947. DOI: <https://doi.org/10.3390/molecules190914919>.
  48. Mohammadshahi M, Haidari F, Soufi FG. Chronic resveratrol administration improves diabetic cardiomyopathy in part by reducing oxidative stress. *Cardiol. J*, 2014, 21: 39–46. DOI: <https://doi.org/10.5603/CJ.a2013.005>.
  49. Roberts VH, Pound LD, Thorn SR, Gillingham MB, Thornburg KL, Friedman JE, Frias AE, et al. Beneficial and cautionary outcomes of resveratrol supplementation in pregnant nonhuman primates. *The FASEB Journal* 2014, 28(6): 2466-2477. DOI: <https://doi.org/10.1096%2Ffj.13-245472>.
  50. Zordoky BN, Robertson IM, Dyck JR. Preclinical and clinical evidence for the role of resveratrol in the treatment of cardiovascular diseases. *Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease* 2015, 1852(6): 1155-1177. DOI: <https://doi.org/10.1016/j.bbadis.2014.10.016>.
  51. Darby JR, Dollah MHM, Regnault TR, Williams MT, Morrison JL. Systematic review: impact of resveratrol exposure during pregnancy on maternal and fetal outcomes in animal models of human pregnancy complications—are we ready for the clinic?. *Pharmacological Research* 2019, 144: 264-278. DOI: <https://doi.org/10.1016/j.phrs.2019.04.020>.
  52. Brawerman GM, Kereliuk SM, Brar N, Cole LK, Seshadri N, Pereira TJ, Xiang B, et al. Maternal resveratrol administration protects against gestational diabetes-induced glucose intolerance and islet dysfunction in the rat

- offspring. *The Journal of physiology* 2019, 597(16): 4175-4192. DOI: <https://doi.org/10.1113/JP278082>.
53. Ros P, Diaz F, Freire-Regatillo A, Argente-Arizon P, Barrios V, Argente J, Chowen JA. Resveratrol intake during pregnancy and lactation modulates the early metabolic effects of maternal nutrition differently in male and female offspring. *Endocrinology* 2018, 159(2): 810-825. DOI: <https://doi.org/10.1210/en.2017-00610>.
  54. Yao L, Wan J, Li H, Ding J, Wang Y, Wang X, Li M. Resveratrol relieves gestational diabetes mellitus in mice through activating AMPK. *Reproductive Biology and Endocrinology* 2015, 13(1): 1-7. DOI: <https://doi.org/10.1186/s12958-015-0114-0>.
  55. Zou T, Chen D, Yang Q, Wang B, Zhu MJ, Nathanielsz PW, Du M. Resveratrol supplementation of high-fat diet-fed pregnant mice promotes brown and beige adipocyte development and prevents obesity in male offspring. *The Journal of physiology* 2017, 595(5):1547-1562. DOI: <https://doi.org/10.1113/JP273478>.
  56. Kayode AAA, Okumede GF, Alabi GO. Mode of action of some bioactive compounds with anticancer activity. *Bioactive Compounds in Health and Disease* 2022, 5(3):67-83. DOI: <https://www.doi.org/10.31989/bchd.v5i2.90>.
  57. Li A, Lin C, Xie F, Jin M, Lin F. Berberine Ameliorates Insulin Resistance by Inhibiting IKK/NF- $\kappa$ B, JNK, and IRS-1/AKT Signaling Pathway in Liver of Gestational Diabetes Mellitus Rats. *Metabolic Syndrome and Related Disorders* 2022, 20(8):480-8. DOI: <https://doi.org/10.1089/met.2022.0017>.
  58. Nagahama K, Utsumi T, Kumano T, Maekawa S, Oyama N, Kawakami J. Discovery of a new function of curcumin which enhances its anticancer therapeutic potency. *Scientific reports* 2016, 6(1): 1-14. DOI: <https://doi.org/10.1038/srep30962>.
  59. Adamczak A, Ożarowski, M, Karpiński T. Curcumin, a natural antimicrobial agent with strain-specific activity. *Pharmaceuticals* 2020, 13(7): 153. DOI: <https://doi.org/10.3390/ph13070153>.
  60. Jakubczyk K, Drużga A, Katarzyna J, Skonieczna-Żydecka K. Antioxidant potential of curcumin—A meta-analysis of randomized clinical trials. *Antioxidants* 2020, 9(11): 1092. DOI: <https://doi.org/10.3390/antiox9111092>.
  61. Kayode AAA, Adebodun GO, Fabunmi DI, Kayode OT. Role of Functional Foods in the Management of Diabetes Mellitus: A Concise Review. *Bioactive Molecules and Pharmaceuticals* 2023, 2(7): 29-42. DOI: <https://www.doi.org/10.31989/bmp.v2i7.1132>.
  62. Soleimani V, Sahebkar A, Hosseinzadeh H. Turmeric (*Curcuma longa*) and its major constituent (curcumin) as nontoxic and safe substances. *Phytotherapy Research*. 2018 Jun;32(6):985-95. DOI: <https://doi.org/10.1002/ptr.6054>.
  63. Lu X, Wu F, Jiang M, Sun X, Tian G. Curcumin ameliorates gestational diabetes in mice partly through activating AMPK. *Pharmaceutical biology* 2019, 57(1): 250-254. DOI: <https://doi.org/10.1080/13880209.2019.1594311>.
  64. Wu J, Ke X, Fu W, Gao X, Zhang H, Wang W, Ma N, et al. Inhibition of hypoxia-induced retinal angiogenesis by specnuezhenide, an effective constituent of *Ligustrum lucidum* Ait., through suppression of the HIF-1 $\alpha$ /VEGF signaling pathway. *Molecules*. 2016 Dec 21;21(12):1756. DOI: <https://doi.org/10.3390/molecules21121756>.
  65. He F, Chen L, Liu Q, Wang X, Li J, Yu J. Preparative separation of phenylethanoid and secoiridoid glycosides from *Ligustri Lucidi Fructus* by high-speed counter-current chromatography coupled with ultrahigh pressure extraction. *Molecules* 2018, 23(12): 3353. DOI: <https://doi.org/10.3390/molecules23123353>.
  66. Yang J, Jia J, Yang Y, Zhao Y, Li Q. Protective effect of Specnuezhenide on islet  $\beta$  cell of rats with gestational diabetes mellitus. *Cellular and Molecular Biology* 2020, 66(1): 60-64. DOI: <https://doi.org/10.14715/cmb/2019.66.1.10>.
  67. Jeong JH, Kim SH, Park MN, Park JY, Park HY, Song CE, Moon JH, Choi AL, Kim KD, Lee NS, Jeong YG. Water extract of mixed mushroom mycelia grown on a solid barley medium is protective against experimental focal cerebral ischemia. *Current Issues in Molecular Biology*. 2021, 43(1):365-83. DOI: <https://doi.org/10.3390/cimb43010030>.
  68. Cör D, Knez Ž, Knez Hrnič M. Antitumour, antimicrobial, antioxidant and antiacetylcholinesterase effect of *Ganoderma lucidum* terpenoids and polysaccharides: A review. *Molecules*. 2018, 23(3):649. DOI: <https://doi.org/10.3390/molecules23030649>.
  69. Chen B, Tian J, Zhang J, Wang K, Liu L, Yang B, Bao L, Liu H. Triterpenes and meroterpenes from *Ganoderma lucidum* with inhibitory activity against HMGs reductase, aldose reductase and  $\alpha$ -glucosidase. *Fitoterapia*. 2017, 120:6-16. DOI: <https://doi.org/10.1016/j.fitote.2017.05.005>.
  70. Viroel FJM, Laurino LF, Caetano ÉLA, Jozala AF, Spim SRV, Pickler TB, Secundes MK, et al. *Ganoderma lucidum* Modulates Glucose, Lipid Peroxidation and Hepatic Metabolism in Streptozotocin-Induced Diabetic Pregnant

- Rats. *Antioxidants* 2022, 11(6): 1035. DOI: <https://doi.org/10.3390/antiox11061035>.
71. Zhang J, Gao X, Pan Y, Xu N, Jia L. Toxicology and immunology of *Ganoderma lucidum* polysaccharides in Kunming mice and Wistar rats. *International journal of biological macromolecules*. 2016 Apr 1;85:302-10. DOI: <https://doi.org/10.1016/j.ijbiomac.2015.12.090>.
  72. Wang C, Wang W, Jin X, Shen J, Hu W, Jiang T. Puerarin attenuates inflammation and oxidation in mice with collagen antibody-induced arthritis via TLR4/NF- $\kappa$ B signaling. *Molecular Medicine Reports* 2016, 14(2): 1365-1370. DOI: <https://doi.org/10.3892/mmr.2016.535>
  73. Li W, Zhao W, Wu Q, Lu Y, Shi J, Chen X. Puerarin improves diabetic aorta injury by inhibiting NADPH oxidase-derived oxidative stress in STZ-induced diabetic rats. *Journal of Diabetes Research* 2016, 2016:8541520. DOI: <https://doi.org/10.1155/2016/8541520>.
  74. Xu W, Tang M, Wang, J, Wang L. Anti-inflammatory activities of puerarin in high-fat diet-fed rats with streptozotocin-induced gestational diabetes mellitus. *Molecular Biology Reports* 2020, 47(10): 7537-7546. DOI: <https://doi.org/10.1007/s11033-020-05816-6>.
  75. Liao CH, Lin JY. Lotus (*Nelumbo nucifera* Gaertn) plumule polysaccharide ameliorates pancreatic islets loss and serum lipid profiles in non-obese diabetic mice. *Food and chemical toxicology* 2013, 58: 416-422. DOI: <https://doi.org/10.1016/j.fct.2013.05.018>.
  76. Zeng Z, Xu Y, Zhang B. Antidiabetic activity of a lotus leaf selenium (Se)-polysaccharide in rats with gestational diabetes mellitus. *Biological trace element research* 2017, 176(2): 321-327. DOI: <https://doi.org/10.1007/s12011-016-0829-6>.
  77. Zhou XL, Kong XF, Yang XJ, Yin YL. Soybean oligosaccharides alter colon short-chain fatty acid production and microbial population in vitro. *Journal of Animal Science* 2012, 90(suppl\_4), 37-39. DOI: <https://doi.org/10.2527/jas.50269>.
  78. Chen H, Li-Jun L, Jian-Jun Z, Bo X, Rui L. Chemical composition analysis of soybean oligosaccharides and its effect on ATPase activities in hyperlipidemic rats. *International journal of biological macromolecules* 2010, 46(2): 229-231. DOI: <https://doi.org/10.1016/j.ijbiomac.2009.12.005>.
  79. Fei BB, Ling L, Hua C, Ren SY. Effects of soybean oligosaccharides on antioxidant enzyme activities and insulin resistance in pregnant women with gestational diabetes mellitus. *Food Chemistry* 2014, 158: 429-432. DOI: <https://doi.org/10.1016/j.foodchem.2014.02.106>.
  80. Jamilian M, Asemi Z. The effect of soy intake on metabolic profiles of women with gestational diabetes mellitus. *The Journal of Clinical Endocrinology & Metabolism* 2015, 100(12): 4654-4661. DOI: <https://doi.org/10.1210/jc.2015-3454>.
  81. Agarwal S, Kovilam O, Agrawal DK. Vitamin D and its impact on maternal-fetal outcomes in pregnancy. A critical review. *Critical reviews in food science and nutrition* 2018, 58(5): 755-769. DOI: <https://doi.org/10.1080/10408398.2016.1220915>.
  82. Jamilian M, Karamali M, Taghizadeh M, Sharifi N, Jafari Z, Memarzadeh MR, Mahlouji M, et al. Vitamin D and evening primrose oil administration improve glycemia and lipid profiles in women with gestational diabetes. *Lipids* 2016, 51(3): 349-356. DOI: <https://doi.org/10.1007/s11745-016-4123-3>.
  83. Backes J, Anzalone D, Hilleman D, Catini J. The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia. *Lipids in Health and Disease* 2016, 15(1): 1-12. DOI: <https://doi.org/10.1186/s12944-016-0286-4>.
  84. Jamilian M, Tabassi Z, Reiner Ž, Panahandeh I, Naderi F, Aghadavod E, Amirani E, et al. The effects of n-3 fatty acids from flaxseed oil on genetic and metabolic profiles in patients with gestational diabetes mellitus: A randomised, double-blind, placebo-controlled trial. *British Journal of Nutrition* 2020, 123(7): 792-799. DOI: <https://doi.org/10.1017/S0007114519003416>.